2 results
Approved WMOCompleted
to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.
Approved WMORecruiting
The primary objective is to identify which coagulation factors are associated with unsuccessful reversal of VKA activity. Secondary objectives include the assessment of the number of patients reaching normalized INR (i.e. <1.8) and the number…